AZTA

Azenta, Inc. 10-Q Summary: Quarter Ended December 31, 2024

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 2024 (Fiscal Q1 2025). Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company operates through two primary continuing segments: Sample Management Solutions and Multiomics. During this quarter, the Company classified its B Medical Systems business as "held for sale" and reported its results as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 4.1% year-over-year, driven by growth in both segments. Multiomics revenue rose 5.7% (driven by Next Generation Sequencing and Gene Synthesis), while Sample Management Solutions revenue increased 2.8%.
• Margin Expansion: Gross margin improved by 300 basis points to 46.6%, attributed to operational efficiencies, favorable sales mix, and the absence of certain non-recurring items recorded in the prior year.
• Operating Expenses: Total operating expenses increased to $80.0 million from $78.0 million. This was primarily due to higher Selling, General, and Administrative (SG&A) expenses (up $3.3 million), partially offset by lower R&D expenses and reduced restructuring charges.
• Discontinued Operations: The B Medical Systems segment generated a loss of $3.9 million for the quarter, a significant improvement from the $8.5 million loss in the prior year period.
• Interest Income: Net interest income decreased to $4.3 million from $10.0 million in the prior year due to a reduction in the portfolio of marketable securities.

Guidance, Outlook, and Risks

• Strategic Divestiture: The Company announced a plan to sell the B Medical Systems business to simplify its portfolio and focus on core life sciences operations. A definitive agreement is anticipated by November 2025.
• Transformation Initiatives: The Company is executing a 2024 restructuring and transformation plan aimed at cost reduction and productivity improvements, expected to conclude by the end of fiscal 2026. Transformation costs of $3.0 million were incurred in the quarter.
• Internal Control Material Weakness: Management identified a material weakness in internal controls over financial reporting related to the review of the cash flow statement. This resulted in immaterial misstatements in prior periods. Remediation efforts, including new automated reporting tools, are underway but have not yet operated long enough to be deemed effective.
• Legal Contingencies: The Company faces ongoing indemnification claims related to the 2018 sale of its semiconductor cryogenics business to Edwards Vacuum. A liability of $1.7 million remains accrued, though management does not believe this will have a material adverse effect on continuing operations.
• Tariff Matters: The Company paid approximately $2.5 million in tariffs and interest in July 2024 related to imports from its GENEWIZ business. Final audit results are expected in Q3 2025.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the timeline and expected proceeds from the sale of the B Medical Systems business and confirm the classification of assets/liabilities held for sale.
• Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness in cash flow statement controls to ensure future reporting accuracy.
• Segment Profitability: Review the trajectory of the Multiomics segment, which remains in an adjusted operating loss position despite revenue growth.
• Legal Exposure: Track developments regarding the Edwards Vacuum indemnification claims to assess potential changes to the accrued liability.
• Cash Flow Quality: Analyze the sustainability of operating cash flows, noting the impact of the $11.5 million U.S. federal tax refund received in the quarter.